<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hepatitis B virus and dialysis patients</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hepatitis B virus and dialysis patients</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hepatitis B virus and dialysis patients</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tak-Mao Chan, MD, DSc, FRCP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steve J Schwab, MD, FACP, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adrian M Di Bisceglie, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 02, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hepatitis B virus (HBV) infection can lead to acute or chronic hepatitis, cirrhosis, and/or hepatocellular carcinoma. Despite the availability of effective vaccines since 1982, HBV infection has remained endemic in many countries. The World Health Organization estimates that in 2019, approximately 296 million people were living with chronic hepatitis B infection worldwide. (See  <a class="medical medical_review" href="/d/html/3627.html" rel="external">"Hepatitis B virus: Clinical manifestations and natural history"</a> and  <a class="medical medical_review" href="/d/html/3630.html" rel="external">"Epidemiology, transmission, and prevention of hepatitis B virus infection"</a>.)</p><p>Among patients on dialysis or who have undergone kidney transplantation, HBV infection presents a distinct clinical problem due to the immunosuppressive effect of kidney failure, increased susceptibility for de novo infection and nosocomial transmission, and the long-term implications of untreated HBV on morbidity and mortality. The natural history of HBV infection in patients on dialysis may also vary according to the timing of infection, genotype, and locality.</p><p>This topic will discuss HBV infection among patients with end-stage kidney disease on dialysis, with an emphasis on hemodialysis since it is associated with a higher risk of nosocomial HBV transmission compared with peritoneal dialysis. Details regarding HBV infection in patients with a kidney transplant and kidney diseases in patients with HBV are presented elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7354.html" rel="external">"Kidney transplantation in adults: Hepatitis B virus infection in kidney transplant recipients"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3119.html" rel="external">"Kidney disease associated with hepatitis B virus infection"</a>.)</p><p></p><p class="headingAnchor" id="H3894290755"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span></p><p class="headingAnchor" id="H1911041289"><span class="h2">Incidence and prevalence</span><span class="headingEndMark"> — </span>The incidence of HBV infection in patients on dialysis has significantly decreased over the past few decades. This is due to the following factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Screening of blood products for hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc)</p><p class="bulletIndent1"><span class="glyph">●</span>Implementation of infection control measures (see <a class="local">'Infection control measures in the dialysis unit'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced need for transfusion after the advent of erythropoiesis-stimulating agents</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis B vaccination (see  <a class="medical medical_review" href="/d/html/1963.html" rel="external">"Immunizations in patients with end-stage kidney disease"</a>)</p><p></p><p>In the United States, the incidence of HBV infection among patients on hemodialysis has declined by approximately 95 percent since the initiation of hepatitis B vaccination. The annual incidence rate of HBV among patients on hemodialysis decreased from 6.2 percent in 1974 to 0.06 percent in 1999 [<a href="#rid1">1</a>] and has been stable since 1995 (0.12 percent in 2002), with a prevalence rate (by HBsAg seropositivity) of 1 percent [<a href="#rid2">2</a>].</p><p>HBsAg positivity rates in patients on dialysis correlate with endemicity in the general population, as illustrated by the prevalence rates within Asia [<a href="#rid3">3,4</a>]. HBsAg prevalence rates in patients on dialysis have been reported as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>1 percent in United States [<a href="#rid2">2</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>5.9 percent in Italy [<a href="#rid5">5</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>12 percent in Brazil [<a href="#rid6">6</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>1.3 to 14.6 percent in the Asian Pacific region (lower rates in countries such as Australia, Japan, and New Zealand; higher rates in countries such as Mongolia, the Philippines, and China) [<a href="#rid4">4</a>]</p><p></p><p class="headingAnchor" id="H1880813474"><span class="h2">Risk factors for HBV infection in dialysis units</span><span class="headingEndMark"> — </span>Independent risk factors for HBV infection among patients on dialysis in nonendemic areas include the following [<a href="#rid7">7,8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of HBsAg-positive patients within the same dialysis unit</p><p class="bulletIndent1"><span class="glyph">●</span>Lack of provision of dedicated hemodialysis machines for HBsAg-positive patients</p><p class="bulletIndent1"><span class="glyph">●</span>A lower than 50 percent prevalence rate of hepatitis B vaccination among patients on dialysis in the same unit</p><p></p><p>Nosocomial transmission is a well-recognized risk for HBV infection in patients on hemodialysis. The preparation of injectable medications on a cart or in a location within the hemodialysis treatment area is associated with a higher incidence rate for HBV infection compared with centers that prepared these medications in a dedicated medication room (2002 incidence rates of 0.27 and 0.06 percent, respectively) [<a href="#rid2">2</a>]. (See <a class="local">'Infection control measures in the dialysis unit'</a> below.)</p><p>Crucial to preventing nosocomial transmission is the implementation of and adherence to:</p><p class="bulletIndent1"><span class="glyph">●</span>Standard or universal precautionary measures (see <a class="local">'Infection control measures in the dialysis unit'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Hemodialysis unit procedures for the prevention of bloodborne infections (see <a class="local">'Infection control measures in the dialysis unit'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis B vaccination of nonimmune individuals (see <a class="local">'Hepatitis B vaccination'</a> below)</p><p></p><p>Outbreaks of HBV infection in dialysis units are most often related to nonadherence to universal precautions, omission of initial and/or periodic HBsAg screening, sharing of multidose vials or blood-contact equipment, or inadequate vaccination, with surface contamination by HBV of shared equipment being a major contributing factor [<a href="#rid9">9</a>]. HBV deoxyribonucleic acid (DNA) has been shown to traverse the dialyzer membrane during high-flux dialysis, but the degree of infectivity of dialysate and ultrafiltrate remains controversial [<a href="#rid10">10-12</a>].</p><p>Patients on peritoneal dialysis have a lower risk of acquiring HBV infection compared with those on long-term hemodialysis. There is a reported 19-fold difference in seroconversion rates [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H1577864502"><span class="h1">ASSESSMENT OF HBV STATUS PRIOR TO INITIATING DIALYSIS</span><span class="headingEndMark"> — </span>All patients starting hemodialysis should be evaluated for HBV infection prior to initiating dialysis. The following serologic testing should be performed: hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc; total or immunoglobulin G [IgG])  (<a class="graphic graphic_table graphicRef60827" href="/d/graphic/60827.html" rel="external">table 1</a>).</p><p>Subsequent management depends upon the results of serologic testing:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-HBs positive (immunity)</strong> – Patients who have an anti-HBs titer ≥10 milli-international units (mIU)/mL have immunity to HBV infection either through vaccination (anti-HBc negative) or through prior infection (anti-HBc positive). Patients with immunity due to vaccination should undergo monitoring of anti-HBs titers to check for waning immunity. Also, these patients should be routinely tested for HBV while on dialysis since seroconversion to HBsAg positive can occur due to waning immunity. (See <a class="local">'Patients without chronic or occult HBV infection'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HBsAg negative, anti-HBc negative, anti-HBs negative (no prior exposure) </strong>– Individuals with no prior exposure to HBV are at risk for nosocomial transmission of HBV in the dialysis unit and should receive vaccination as soon as possible. Such patients should also be routinely tested for HBV while on dialysis. For those who refuse vaccination, additional monitoring may be indicated. (See <a class="local">'Patients without chronic or occult HBV infection'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HBsAg positive (chronic HBV) </strong>– Patients who are HBsAg positive have acute or chronic HBV infection. Such patients should be dialyzed in an area that is segregated from the main dialysis unit and require special infection control measures to prevent the transmission of HBV to other patients and staff. It should be noted that not all dialysis units may have the resources to dialyze patients with chronic HBV infection. (See <a class="local">'Infection control measures in the dialysis unit'</a> below and <a class="local">'Patients with chronic HBV infection'</a> below.)</p><p></p><p class="bulletIndent1">For patients newly diagnosed with chronic HBV, further testing includes an assessment of hepatitis B e antigen (HBeAg) status, the HBV DNA level, and the presence or absence of cirrhosis. (See  <a class="medical medical_review" href="/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management", section on 'Initial evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isolated anti-HBc positive </strong>– Patients who are negative for both HBsAg and anti-HBs and positive for anti-HBc are referred to as isolated anti-HBc positive. In such patients, we measure a circulating HBV DNA level to better assess HBV status and infectivity. Those who are negative for HBsAg but have detectable HBV DNA are considered to have occult HBV infection, which often represents a low viral replicative state. Isolated anti-HBc positivity can also occur as a transient phenomenon in acute HBV infection, in which case the anti-HBc is of the immunoglobulin M (IgM) isotype. (See  <a class="medical medical_review" href="/d/html/3680.html" rel="external">"Hepatitis B virus: Screening and diagnosis in adults", section on 'Occult HBV infection'</a>.)</p><p></p><p class="bulletIndent1">Occult hepatitis B is relatively uncommon among patients on hemodialysis, affecting fewer than 3 percent, and the incidence correlates with the local prevalence of HBV carriers. However, occult HBV infection presents a risk for nosocomial transmission; thus, it is recommended that HBsAg-negative, HBV DNA-positive patients be segregated during dialysis with those who are HBsAg-positive [<a href="#rid14">14-17</a>]. (See <a class="local">'Infection control measures in the dialysis unit'</a> below and <a class="local">'Patients with occult HBV infection'</a> below.)</p><p></p><p class="headingAnchor" id="H1370794638"><span class="h1">INFECTION CONTROL MEASURES IN THE DIALYSIS UNIT</span><span class="headingEndMark"> — </span>In contrast to other bloodborne infections, the circulating load of HBV can be high in hepatitis B surface antigen (HBsAg)-positive individuals, and the virus can survive on environmental surfaces for a week or longer [<a href="#rid18">18</a>]. Consequently, patients on dialysis, in particular those on hemodialysis, are at risk for nosocomial HBV infection. Nosocomial HBV infection among hemodialysis patients has been related to inadequate infection control measures or technical breaks [<a href="#rid19">19,20</a>]. (See <a class="local">'Risk factors for HBV infection in dialysis units'</a> above.)</p><p>To prevent nosocomial transmission, standard precautionary measures must be rigorously followed [<a href="#rid21">21</a>]. These include barrier procedures to prevent exposure to bloodborne micro-organisms:</p><p class="bulletIndent1"><span class="glyph">●</span>Washing hands after contact with potentially infectious surface or material</p><p class="bulletIndent1"><span class="glyph">●</span>Wearing gloves when contacting potentially infectious surface or material</p><p class="bulletIndent1"><span class="glyph">●</span>Wearing a face mask and gown when exposure to blood or body fluids is expected</p><p></p><p>In addition to these standard precautions, measures specific to hemodialysis units are also important to prevent nosocomial HBV infection [<a href="#rid22">22,23</a>]. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Wearing gloves before contact with patients or dialysis equipment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Routine cleaning and disinfection procedures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prohibition of sharing instruments or medications among patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preparing and distributing medications from a centralized area to avoid moving from patient to patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoiding the use of medication supply carts.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Regular screening of HBsAg status in nonimmune individuals. (See <a class="local">'Surveillance'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis B vaccination of patients and staff. (See <a class="local">'Hepatitis B vaccination'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Healthcare workers handling the dialysis of patients with chronic HBV should not carry out clinical procedures for patients without HBV infection at the same session.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Isolation of patients with chronic (HBsAg-positive) or occult HBV infection during dialysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Regular auditing of infection control policies and practices to ensure adherence.</p><p></p><p>Treatment of HBV-infected patients on hemodialysis with antiviral therapy may also reduce the risk of other patients in the same hemodialysis center acquiring HBV infection [<a href="#rid24">24</a>]. This is consistent with the well-established association between the risk of nosocomial transmission and the prevalence of HBsAg-positive patients in a hemodialysis center.</p><p>Failure to segregate and use dedicated hemodialysis machines for HBsAg-positive patients is associated with an increased incidence of HBV infection, and machine segregation is now standard practice. On the other hand, the United States national surveillance in 1997 showed no difference in the incidence of HBV infection between centers that practiced segregation of dialysis rooms and those that did not [<a href="#rid7">7,25</a>]. Dialyzer reuse was also not associated with a higher risk of HBV infection both in patients and in staff. Nevertheless, the Centers for Disease Control recommended that dialyzers from HBsAg-positive patients be excluded from reuse programs [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H948055388"><span class="h1">DISEASE-SPECIFIC CONSIDERATIONS</span></p><p class="headingAnchor" id="H2710209623"><span class="h2">Patients with chronic HBV infection</span><span class="headingEndMark"> — </span>The clinical manifestations of chronic HBV infection or HBV-induced cirrhosis in patients on dialysis are identical to those in patients without kidney failure. (See  <a class="medical medical_review" href="/d/html/3627.html" rel="external">"Hepatitis B virus: Clinical manifestations and natural history"</a>.)</p><p class="headingAnchor" id="H3510538453"><span class="h3">Enhanced infection control precautions</span><span class="headingEndMark"> — </span>Patients with chronic HBV infection should be dialyzed in an area that is isolated from the main dialysis unit. Other infection control measures are discussed in more detail above. (See <a class="local">'Infection control measures in the dialysis unit'</a> above.)</p><p class="headingAnchor" id="H3345797477"><span class="h3">Routine monitoring</span><span class="headingEndMark"> — </span>Patients with chronic HBV infection on dialysis should have regular monitoring of liver enzymes, serum albumin, and bilirubin concentration. Some UpToDate contributors measure these tests every 12 weeks in patients on dialysis since such patients are prone to various complications and exposed to multiple medications, whereas other experts may measure these tests less frequently (eg, every three to six months). Prothrombin time and international normalized ratio (INR) should also be measured when there is evidence of severe hepatitis or cirrhosis. Parenchymal liver enzymes are measured as a measure of hepatitic activity, while albumin, prothrombin time/INR, and bilirubin are useful indicators of liver function in patients with cirrhosis. We repeat hepatitis B surface antigen (HBsAg) testing annually and perform testing for HBV DNA, hepatitis B e antigen (HBeAg), and hepatitis B e antibody (anti-HBe) when clinically indicated. (See  <a class="medical medical_review" href="/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management"</a>.)</p><p>With regard to screening for hepatocellular carcinoma, existing guidelines recommend surveillance ultrasonography every six months in HBV-infected patients with cirrhosis or at high risk of hepatocellular carcinoma, with or without additional measurement of serum alpha-fetoprotein; alpha-fetoprotein alone is not recommended, except in places where ultrasonography is not available, in view of its lower sensitivity, specificity, and diagnostic accuracy compared with ultrasonography [<a href="#rid27">27</a>]. Risk factors for hepatocellular carcinoma include the presence of cirrhosis, age over 40 years for Asian or Black males or over 50 years for Asian females, hepatocellular carcinoma in a first-degree relative, and coinfection with hepatitis delta virus. While kidney failure is associated with increased overall cancer risk, its impact on the incidence of hepatocellular carcinoma in HBV-endemic areas remains undefined [<a href="#rid28">28,29</a>]. In noncirrhotic patients without established risk factors for hepatocellular carcinoma, the need for monitoring is unclear. Some UpToDate contributors perform a liver ultrasound annually and measure a serum alpha-fetoprotein level every six months. </p><p>Laboratory testing during the acute or chronic phases of HBV infection can reveal elevations in the concentration of alanine and aspartate aminotransferase levels (ALT and AST). However, hypotransaminasemia is a well-recognized feature in patients on dialysis with or without liver disease [<a href="#rid30">30</a>]. Consequently, the normal range of transaminases should be adjusted downwards; otherwise, the incidence or severity of clinical liver disease might be underestimated. In this regard, levels of 24 and 17 units/L have been recommended as the upper limits of normal for AST and ALT, respectively, in patients on dialysis. (See  <a class="medical medical_review" href="/d/html/1895.html" rel="external">"Serum enzymes in patients with kidney failure"</a>.)</p><p>Since the biochemical abnormalities (eg, transaminitis) do not always correlate with liver histology, a liver biopsy may be necessary in selected patients, with careful attention to minimize the risk of bleeding complications [<a href="#rid31">31,32</a>]. In this regard, transient elastography has increasingly replaced liver biopsy in the assessment of liver fibrosis due to viral hepatitis, especially since the optimal timing of liver biopsy in otherwise asymptomatic patients without clinical or biochemical abnormalities remains to be defined [<a href="#rid33">33</a>]. Data suggest that transient elastography should be performed postdialysis since fluid removal during dialysis decreases the value of liver stiffness measurement [<a href="#rid34">34,35</a>]. </p><p class="headingAnchor" id="H363327392"><span class="h3">Treatment of chronic HBV</span><span class="headingEndMark"> — </span>For patients with chronic HBV, the indications for treatment typically depend upon the HBV DNA level, the transaminase levels, and the presence of liver injury, including cirrhosis. In general, the indications for HBV treatment are the same for those with and without kidney failure. (See  <a class="medical medical_review" href="/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management"</a>.)</p><p></p><p>However, certain patients on dialysis may be receiving immunosuppressive agents to treat their underlying condition. For such patients, treatment is typically indicated, regardless of the HBV DNA level or aminotransaminase levels given the risk of a flare of their HBV infection due to the immunosuppressive therapy. Similarly, when a kidney transplant with its associated use of immunosuppression can be anticipated in the near future, initiation of antiviral therapy may also be considered. (See  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p>Patients requiring antiviral therapy should be treated with an agent that has a high barrier to resistance. For those on dialysis, tenofovir (<a class="drug drug_general" data-topicid="9895" href="/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a> or <a class="drug drug_general" data-topicid="110861" href="/d/drug information/110861.html" rel="external">tenofovir alafenamide</a>) or <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> can be used. Dose adjustments are described in the table  (<a class="graphic graphic_table graphicRef71024" href="/d/graphic/71024.html" rel="external">table 2</a>). Additional information on the use of these agents in patients with kidney failure can be found in the Lexicomp drug information topics within UpToDate. (See  <a class="medical medical_review" href="/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management", section on 'Choice of initial agent'</a>.)</p><p class="headingAnchor" id="H2507705694"><span class="h3">Prognosis</span><span class="headingEndMark"> — </span>Although early data suggested inferior clinical outcomes in HBV-infected patients on dialysis [<a href="#rid36">36</a>], the majority of more recent studies have not indicated significant differences in morbidity and mortality between HBsAg-positive and HBsAg-negative patients on dialysis, especially after the advent of antiviral therapies [<a href="#rid37">37,38</a>]. Fewer than 5 percent of these patients die from liver disease [<a href="#rid37">37,38</a>]. The adverse impact of HBV infection on the survival rate of patients on dialysis appears much lower compared with that of bacterial infections and vascular complications, which are the leading causes of death.</p><p>Cirrhosis of any cause is associated with a 35 percent increase in mortality rate among patients on dialysis; however, whether HBV infection alone contributes to this effect on patient survival remains controversial [<a href="#rid37">37,39,40</a>]. </p><p class="headingAnchor" id="H245242355"><span class="h2">Patients with occult HBV infection</span><span class="headingEndMark"> — </span>Similar to patients with chronic HBV infection, patients with occult HBV and measurable HBV DNA in serum should be dialyzed in an area that is isolated from the main dialysis unit, and they require special infection control measures to prevent the transmission of HBV to other patients and staff. Routine monitoring is similar to that for patients with chronic HBV, as described above. (See <a class="local">'Infection control measures in the dialysis unit'</a> above and <a class="local">'Routine monitoring'</a> above.)</p><p class="headingAnchor" id="H835736366"><span class="h2">Patients without chronic or occult HBV infection</span><span class="headingEndMark"> — </span>Patients on dialysis who do not have evidence of chronic or occult HBV infection include those with HBV immunity through vaccination or prior infection, those with no prior HBV infection, and those who are hepatitis B core antibody (anti-HBc) positive and HBV DNA negative  (<a class="graphic graphic_table graphicRef60827" href="/d/graphic/60827.html" rel="external">table 1</a>). Patients with no prior infection should be vaccinated to reduce the risk of acquiring HBV infection. However, since hepatitis B vaccination is less effective in those on dialysis, routine surveillance testing to detect new HBV infection or the need for a booster dose of the hepatitis B vaccine should be performed. </p><p class="headingAnchor" id="H1144083849"><span class="h3">Hepatitis B vaccination</span><span class="headingEndMark"> — </span>Individuals with no prior exposure to HBV are at risk for nosocomial transmission of HBV in the dialysis unit and should receive vaccination as soon as possible. Vaccination is important both to prevent susceptible patients from acquiring HBV and to reduce the pool of HBV-infected patients. In a case-control study, the risk of HBV infection in patients on hemodialysis was reduced by 70 percent after hepatitis B vaccination [<a href="#rid41">41</a>]. It is imperative that HBV vaccination be performed early in the course of kidney failure in nonimmune subjects since seroconversion response correlates with the level of kidney function and is significantly lower in patients on dialysis, who require higher doses of vaccine or other measures to increase the vaccination response [<a href="#rid42">42</a>]. A booster dose of vaccine can be given to patients who are isolated anti-HBc positive but HBV DNA negative to see if it stimulates the production of hepatitis B surface antibody (anti-HBs). Issues surrounding hepatitis B vaccination in patients on dialysis are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1963.html" rel="external">"Immunizations in patients with end-stage kidney disease", section on 'Hepatitis B virus vaccine'</a> and  <a class="medical medical_review" href="/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults", section on 'Patients on dialysis and immunocompromised hosts'</a>.)</p><p class="headingAnchor" id="H2271893576"><span class="h3">Surveillance</span></p><p class="headingAnchor" id="H1687639356"><span class="h4">New HBV infection</span><span class="headingEndMark"> — </span>All patients without chronic or occult HBV infection should be routinely monitored for the development of new HBV infection:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory testing </strong>– Patients should undergo routine testing for HBsAg to detect new HBV infection. The frequency of testing depends upon the patient's HBV serology profile and may also vary among dialysis units. At our center, we perform HBsAg testing every three months. In certain patients, such as those with an anti-HBs titer &gt;100 milli-international units (mIU)/mL, the frequency of testing can be extended to once every six months, but for ease of implementation, dialysis units may prefer to routinely check HBsAg every three months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical monitoring for acute infection </strong>– Clinicians and patients should be alert to signs and symptoms of HBV infection since the manifestation of acute HBV infection in patients on dialysis is extremely variable. The majority of patients on dialysis with new HBV infection are either asymptomatic or have mild clinical symptoms [<a href="#rid36">36</a>]. Serum transaminase levels are either normal or only slightly elevated. This also relates to the lower values of the normal range in these patients. It is not uncommon that the diagnosis of HBV infection is made through regular surveillance testing. (See  <a class="medical medical_review" href="/d/html/1895.html" rel="external">"Serum enzymes in patients with kidney failure", section on 'Aminotransferases'</a>.)</p><p></p><p class="bulletIndent1">The genetic variant of HBV may affect the severity of clinical manifestations. As an example, an outbreak of fulminant hepatitis resulting in four deaths in a dialysis center in Tokyo was attributed to infection by a precore mutant [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1">Acute hepatitis B in patients on dialysis is more likely to result in chronic infection compared with nonimmunosuppressed individuals. Up to 80 percent of acutely infected patients on dialysis may become chronic carriers [<a href="#rid36">36</a>].</p><p></p><p class="headingAnchor" id="H140858282"><span class="h4">Waning immunity</span><span class="headingEndMark"> — </span>All patients with immunity to HBV should undergo routine testing for anti-HBs at least annually to detect waning immunity and determine the need for a booster dose of the hepatitis B vaccine. We administer a booster vaccine dose when the anti-HBs level drops below 10 mIU/mL. This is often given to those with immunity due to vaccination, especially when kidney transplantation in the near future is anticipated. Some experts also give a booster dose to those with waning immunity due to prior infection since there is a potential benefit and vaccination is well tolerated; however, there are limited data supporting this approach and vaccination of those with prior infection is not routinely done in all dialysis centers.  </p><p class="headingAnchor" id="H3149079012"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment of HBV status prior to dialysis initiation </strong>– All patients starting hemodialysis should be evaluated for hepatitis B virus (HBV) infection prior to initiating dialysis with the following serologic testing: hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc; total or IgG)  (<a class="graphic graphic_table graphicRef60827" href="/d/graphic/60827.html" rel="external">table 1</a>). Subsequent management depends upon the results of testing. (See <a class="local">'Assessment of HBV status prior to initiating dialysis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection control measures </strong>– Patients on hemodialysis are at risk for nosocomial HBV infection, usually related to inadequate infection control measures or technical breaks. To prevent nosocomial transmission, standard precautionary measures as well as measures specific to hemodialysis units must be rigorously followed. (See <a class="local">'Infection control measures in the dialysis unit'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management based on HBV serologic status</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with chronic HBV </strong>– Patients with chronic HBV infection are HBsAg positive. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Enhanced infection control precautions </strong>– Patients with chronic HBV infection should be dialyzed in an area that is isolated from the main dialysis unit. (See <a class="local">'Enhanced infection control precautions'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Monitoring </strong>– Patients with chronic HBV should have regular monitoring of liver enzymes, serum albumin, and bilirubin, at least once every 12 weeks. Prothrombin time should also be measured when there is evidence of severe hepatitis or cirrhosis. We repeat HBsAg testing annually and perform testing for HBV DNA, hepatitis B e antigen (HBeAg), and hepatitis B e antibody (anti-HBe) when clinically indicated. With regard to screening for hepatocellular carcinoma, we perform a liver ultrasound every six months in patients with cirrhosis or other risk factors for hepatocellular carcinoma; in other patients, liver ultrasound is done annually, with serum alpha-fetoprotein level measured every six months. (See <a class="local">'Routine monitoring'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Treatment </strong>– The indications for treatment typically depend upon the HBV DNA level, the transaminase levels, and the presence of cirrhosis. Patients requiring therapy should be treated with an agent that has a high barrier to resistance, such as tenofovir or <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a>. (See  <a class="medical medical_review" href="/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management", section on 'Choice of initial agent'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with occult HBV</strong> – Patients who are negative for HBsAg, are positive for anti-HBc, and have detectable HBV DNA are considered to have occult HBV infection, which often represents a low viral replicative state. Similar to patients with chronic HBV, patients with occult HBV should be dialyzed in an area that is isolated from the main dialysis unit and require special infection control measures to prevent the transmission of HBV to other patients and staff. Routine monitoring is similar to that for patients with chronic HBV. (See <a class="local">'Patients with occult HBV infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients without chronic or occult HBV </strong>– Patients on dialysis who do not have evidence of chronic or occult HBV infection include those with HBV immunity through vaccination or prior infection, those with no prior HBV infection, and those who are anti-HBc positive and HBV DNA-negative.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>HBV vaccination </strong>– Patients with no prior infection should be vaccinated to reduce the risk of acquiring HBV infection. However, hepatitis B vaccination is less effective in patients with kidney failure. (See <a class="local">'Hepatitis B vaccination'</a> above.)</p><p></p><p class="bulletIndent3">A booster dose of vaccine is also reasonable for patients who are isolated anti-HBc positive but HBV DNA negative, to see if it stimulates the production of anti-HBs. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Surveillance </strong>– All patients without chronic or occult HBV infection should be routinely monitored for the development of new HBV infection. The frequency of testing, ranging from every three to six months, depends upon the patient's HBV serology profile and may also vary among dialysis units. Clinicians and patients should be alert to signs and symptoms of HBV infection. All patients with immunity should undergo routine testing for anti-HBs at least annually to detect waning immunity and determine the need for a booster dose of the hepatitis B vaccine. We administer a booster vaccine dose when the anti-HBs level drops below 10 milli-international units (mIU)/mL. (See <a class="local">'Surveillance'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Alter MJ, Favero MS, Maynard JE. Impact of infection control strategies on the incidence of dialysis-associated hepatitis in the United States. J Infect Dis 1986; 153:1149.</a></li><li><a class="nounderline abstract_t">Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18:52.</a></li><li><a class="nounderline abstract_t">Oguchi H, Miyasaka M, Tokunaga S, et al. Hepatitis virus infection (HBV and HCV) in eleven Japanese hemodialysis units. Clin Nephrol 1992; 38:36.</a></li><li><a class="nounderline abstract_t">Johnson DW, Dent H, Yao Q, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant 2009; 24:1598.</a></li><li><a class="nounderline abstract_t">Mioli VA, Balestra E, Bibiano L, et al. Epidemiology of viral hepatitis in dialysis centers: a national survey. Nephron 1992; 61:278.</a></li><li><a class="nounderline abstract_t">Teles SA, Martins RM, Vanderborght B, et al. Hepatitis B virus: genotypes and subtypes in Brazilian hemodialysis patients. Artif Organs 1999; 23:1074.</a></li><li><a class="nounderline abstract_t">Tokars JI, Alter MJ, Miller E, et al. National surveillance of dialysis associated diseases in the United States--1994. ASAIO J 1997; 43:108.</a></li><li><a class="nounderline abstract_t">Burdick RA, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2003; 63:2222.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Outbreaks of hepatitis B virus infection among hemodialysis patients-- California, Nebraska, and Texas, 1994. MMWR Morb Mortal Wkly Rep 1996; 45:285.</a></li><li><a class="nounderline abstract_t">Andrew R, Hariharan S, Saha V, et al. Biochemical evaluation of ultrafiltrate in dialysis-dependent HBsAG-positive patients. Nephron 1988; 49:88.</a></li><li><a class="nounderline abstract_t">Kroes AC, van Bommel EF, Niesters HG, Weimar W. Hepatitis B viral DNA detectable in dialysate. Nephron 1994; 67:369.</a></li><li><a class="nounderline abstract_t">Fabrizi F, Dixit V, Messa P, Martin P. Transmission of hepatitis B virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs 2015; 38:1.</a></li><li><a class="nounderline abstract_t">Cendoroglo Neto M, Draibe SA, Silva AE, et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant 1995; 10:240.</a></li><li><a class="nounderline abstract_t">Sowole L, Labbett W, Patel M, et al. The prevalence of occult hepatitis B virus (HBV) infection in a large multi-ethnic haemodialysis cohort. BMC Nephrol 2015; 16:12.</a></li><li><a class="nounderline abstract_t">Saijo T, Joki N, Inishi Y, et al. Occult hepatitis B virus infection in hemodialysis patients in Japan. Ther Apher Dial 2015; 19:125.</a></li><li><a class="nounderline abstract_t">Kim SM, Kim HW, Lee JE, et al. Occult hepatitis B virus infection of hemodialysis patients: a cross-sectional study in a hepatitis B virus-endemic region. Hemodial Int 2015; 19:66.</a></li><li><a class="nounderline abstract_t">Lin H, Zhao H, Tang X, et al. Serological Patterns and Molecular Characterization of Occult Hepatitis B Virus Infection among Blood Donors. Hepat Mon 2016; 16:e40492.</a></li><li><a class="nounderline abstract_t">Favero MS, Bond WW, Petersen NJ, et al. Detection methods for study of the stability of hepatitis B antigen on surfaces. J Infect Dis 1974; 129:210.</a></li><li><a class="nounderline abstract_t">Niu MT, Penberthy LT, Alter MJ, et al. Hemodialysis-associated hepatitis B: report of an outbreak. Dial Transplant 1989; 18:542.</a></li><li><a class="nounderline abstract_t">Alter MJ, Ahtone J, Maynard JE. Hepatitis B virus transmission associated with a multiple-dose vial in a hemodialysis unit. Ann Intern Med 1983; 99:330.</a></li><li><a class="nounderline abstract_t">Kellerman S, Alter MJ. Preventing hepatitis B and hepatitis C virus infections in end-stage renal disease patients: back to basics. Hepatology 1999; 29:291.</a></li><li><a class="nounderline abstract_t">Garthwaite E, Reddy V, Douthwaite S, et al. Clinical practice guideline management of blood borne viruses within the haemodialysis unit. BMC Nephrol 2019; 20:388.</a></li><li class="breakAll">CDC Guidelines and Recommendations on Dialysis Safety. Available at: https://www.cdc.gov/dialysis/guidelines/index.html (Accessed on May 05, 2022).</li><li><a class="nounderline abstract_t">Goodkin DA, Young EW, Kurokawa K, et al. Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis 2004; 44:16.</a></li><li><a class="nounderline abstract_t">Tokars JI, Finelli L, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2001. Semin Dial 2004; 17:310.</a></li><li class="breakAll">Centers for Disease Control. Control measures for hepatitis B in dialysis centers. Virus hepatitis investigations and control series, Centers for Disease Control and Prevention, Atlanta, GA 1977.</li><li><a class="nounderline abstract_t">Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67:1560.</a></li><li><a class="nounderline abstract_t">Fabrizi F, Cerutti R, Alfieri CM, Ridruejo E. An Update on Hepatocellular Carcinoma in Chronic Kidney Disease. Cancers (Basel) 2021; 13.</a></li><li><a class="nounderline abstract_t">Hwang JC, Weng SF, Weng RH. High incidence of hepatocellular carcinoma in ESRD patients: caused by high hepatitis rate or 'uremia'? a population-based study. Jpn J Clin Oncol 2012; 42:780.</a></li><li><a class="nounderline abstract_t">Yasuda K, Okuda K, Endo N, et al. Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. Gastroenterology 1995; 109:1295.</a></li><li><a class="nounderline abstract_t">Degott C, Degos F, Jungers P, et al. Relationship between liver histopathological changes and HBsAg in 111 patients treated by long-term hemodialysis. Liver 1983; 3:377.</a></li><li><a class="nounderline abstract_t">Ozdoğan M, Ozgür O, Gür G, et al. Histopathological impacts of hepatitis virus infection in hemodialysis patients: should liver biopsy be performed before renal transplantation? Artif Organs 1997; 21:355.</a></li><li><a class="nounderline abstract_t">Lee JJ, Wei YJ, Lin MY, et al. The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C. PLoS One 2020; 15:e0242601.</a></li><li><a class="nounderline abstract_t">Kellner P, Anadol E, Hüneburg R, et al. The effect of hemodialysis on liver stiffness measurement: a single-center series. Eur J Gastroenterol Hepatol 2013; 25:368.</a></li><li><a class="nounderline abstract_t">Taneja S, Borkakoty A, Rathi S, et al. Assessment of Liver Fibrosis by Transient Elastography Should Be Done After Hemodialysis in End Stage Renal Disease Patients with Liver Disease. Dig Dis Sci 2017; 62:3186.</a></li><li><a class="nounderline abstract_t">Harnett JD, Parfrey PS, Kennedy M, et al. The long-term outcome of hepatitis B infection in hemodialysis patients. Am J Kidney Dis 1988; 11:210.</a></li><li><a class="nounderline abstract_t">Josselson J, Kyser BA, Weir MR, Sadler JH. Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality. Am J Kidney Dis 1987; 9:456.</a></li><li><a class="nounderline abstract_t">Ow MM, de Zoysa JR, Gane EJ. The impact of oral antiviral therapy on long-term survival of hepatitis B surface antigen-positive patients on haemodialysis. N Z Med J 2014; 127:34.</a></li><li><a class="nounderline abstract_t">Held PJ, Port FK, Turenne MN, et al. Continuous ambulatory peritoneal dialysis and hemodialysis: comparison of patient mortality with adjustment for comorbid conditions. Kidney Int 1994; 45:1163.</a></li><li><a class="nounderline abstract_t">Jha R, Kher V, Naik S, et al. Hepatitis B associated liver disease in dialysis patients: role of vaccination. J Nephrol 1993; 6:98.</a></li><li><a class="nounderline abstract_t">Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis 1999; 33:356.</a></li><li><a class="nounderline abstract_t">DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003; 42:1184.</a></li><li><a class="nounderline abstract_t">Tanaka S, Yoshiba M, Iino S, et al. A common-source outbreak of fulminant hepatitis B in hemodialysis patients induced by precore mutant. Kidney Int 1995; 48:1972.</a></li></ol></div><div id="topicVersionRevision">Topic 1931 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3701120" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Impact of infection control strategies on the incidence of dialysis-associated hepatitis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15663766" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : National surveillance of dialysis-associated diseases in the United States, 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1499167" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hepatitis virus infection (HBV and HCV) in eleven Japanese hemodialysis units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19096083" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1386900" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Epidemiology of viral hepatitis in dialysis centers: a national survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10619925" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hepatitis B virus: genotypes and subtypes in Brazilian hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9116344" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : National surveillance of dialysis associated diseases in the United States--1994.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12753311" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8598825" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Outbreaks of hepatitis B virus infection among hemodialysis patients-- California, Nebraska, and Texas, 1994.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3380225" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Biochemical evaluation of ultrafiltrate in dialysis-dependent HBsAG-positive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7936036" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hepatitis B viral DNA detectable in dialysate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25633894" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Transmission of hepatitis B virus in dialysis units: a systematic review of reports on outbreaks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7538651" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25884422" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The prevalence of occult hepatitis B virus (HBV) infection in a large multi-ethnic haemodialysis cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25363685" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Occult hepatitis B virus infection in hemodialysis patients in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25196802" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Occult hepatitis B virus infection of hemodialysis patients: a cross-sectional study in a hepatitis B virus-endemic region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27882070" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Serological Patterns and Molecular Characterization of Occult Hepatitis B Virus Infection among Blood Donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4810942" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Detection methods for study of the stability of hepatitis B antigen on surfaces.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hemodialysis-associated hepatitis B: report of an outbreak</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6614681" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hepatitis B virus transmission associated with a multiple-dose vial in a hemodialysis unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9862883" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Preventing hepatitis B and hepatitis C virus infections in end-stage renal disease patients: back to basics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31656166" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical practice guideline management of blood borne viruses within the haemodialysis unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31656166" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical practice guideline management of blood borne viruses within the haemodialysis unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15486869" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15250925" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : National surveillance of dialysis-associated diseases in the United States, 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15250925" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : National surveillance of dialysis-associated diseases in the United States, 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29405329" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34298832" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : An Update on Hepatocellular Carcinoma in Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22782961" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : High incidence of hepatocellular carcinoma in ESRD patients: caused by high hepatitis rate or 'uremia'? a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7557098" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6366422" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Relationship between liver histopathological changes and HBsAg in 111 patients treated by long-term hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9129765" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Histopathological impacts of hepatitis virus infection in hemodialysis patients: should liver biopsy be performed before renal transplantation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33216807" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23114792" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The effect of hemodialysis on liver stiffness measurement: a single-center series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28948504" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Assessment of Liver Fibrosis by Transient Elastography Should Be Done After Hemodialysis in End Stage Renal Disease Patients with Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3344743" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The long-term outcome of hepatitis B infection in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3591792" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24997462" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The impact of oral antiviral therapy on long-term survival of hepatitis B surface antigen-positive patients on haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8007587" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Continuous ambulatory peritoneal dialysis and hemodialysis: comparison of patient mortality with adjustment for comorbid conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hepatitis B associated liver disease in dialysis patients: role of vaccination</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10023650" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Protective effect of hepatitis B vaccine in chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14655190" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8587260" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A common-source outbreak of fulminant hepatitis B in hemodialysis patients induced by precore mutant.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
